Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User fee increase of about 20% under discussion between FDA and industry.

This article was originally published in The Tan Sheet

Executive Summary

FDA/INDUSTRY USER FEE REAUTHORIZATION DISCUSSIONS FOCUSING ON 20% RAISE in user fees as the agency and brand-name pharmaceutical industry seek to reach an agreement in time for the opening of the 105th Congress. FDA is understood to have been seeking roughly a doubling of the fees in exchange for expanded services. The agency, however, could be willing to accept an increase of about 20% to cover a lesser package of commitments on the review process.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel